SuperworthIB Acquisition market cap IBAC
Share price times shares outstanding: what the whole company sells for, since 2024.
- Today, Oct 23, 2026
- $54.4M
- Highest close in our data
- $166.6M
- Sep 2025
IB Acquisition is worth $54.4M at the close on Oct 23, 2026, at $10.86 a share.
That is down 67% over the last year.
Its highest close in our data was $166.6M in Sep 2025.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $54.4M | $53.7M | $62.2M | −67% |
| 2025 | $164.6M | $159.5M | $166.6M | +3% |
| 2024 | $159.4M | $156.9M | $159.5M | n/a |
Against its peers
Companies in Healthcare nearest IB Acquisition's size, closest first, today.
| Company | Market cap |
|---|---|
| IBACIB Acquisition | $54.4M |
| APTAlpha Pro Tech | $56.7M |
| ATNMActinium Pharmaceuticals | $47.8M |
| SPROSpero Therapeutics | $64.6M |
| LFVNLifevantage | $73.4M |
| NEPHNephros | $38.3M |
| ICCCImmucell | $93.1M |
| KEQUKewaunee Scientific | $94.9M |
| PDEXPro DEX | $199.3M |
| PLXProtalix BioTherapeutics | $205.5M |
| NATRNatures Sunshine Products | $213.8M |
| Peer median | $83.3M |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on IB Acquisition
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.